Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645513 | 0.88 | PDE4A (0.54) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL4646945 | 0.87 | PDE4D (0.53) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4642754 | 0.85 | PDE4A (0.52) | PDE4APDE4DPDE4BPDE4CGAK | |
| SCHEMBL4642832 | 0.85 | PDE4D (0.56) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4648555 | 0.84 | PDE4A (0.50) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4645355 | 0.83 | PDE4A (0.55) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4642752 | 0.82 | PDE4B (0.53) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4648219 | 0.82 | PDE4A (0.48) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4644885 | 0.82 | PDE4D (0.53) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL4645023 | 0.81 | PDE4A (0.53) | PDE4APDE4DPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | claimed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | claimed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1958947-A1 | Inhibitors of phosphodiesterase type 4 | Ranbaxy Laboratories Limited (IN) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4D 6/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.